Recall of Burlington Medical Frontal Aprons for Attenuation Degradation

Source: FDA · United States

Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.

Burlington Medical, LLC is recalling 14,323 Frontal Aprons due to potential attenuation degradation that could shorten their lifespan, affecting devices distributed nationwide in the US and internationally.

What this FDA recall tells you, and what most readers miss

This notice was issued by FDA on April 15, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.

Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.

Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, Devices.

What Happened

Burlington Medical, LLC is initiating a voluntary recall of their Frontal Aprons due to the potential for attenuation degradation over time, which decreases the product's lifespan.

Which Products Are Affected

The affected products are Burlington Medical Frontal Aprons, with a total of 14,323 units. These were manufactured from January 16, 2025, to January 21, 2026, and include all serial numbers made with Xenolite 800 attenuation material. Specific models include: C8F17, R8601, R8A10, R8F01, R8F17, R8P500, S8601, S8A10, S8F01, S8F17, U8601, U8A10, U8F01, and U8F17. Associated UDI-DIs and product codes are listed in the recall details, such as 00840331297706 for various C8F17 variants and 00197513001287 for R8P500-LG.

What You Should Do

Consumers should follow the initial firm notification, which was sent via letter, and contact Burlington Medical, LLC at their address: 3 Elmhurst St, Suite 112, Newport News, VA 23603-1137, for instructions on returns or refunds related to this recall.

Why This Matters

This recall involves medical devices that may not provide adequate protection due to degradation, potentially affecting user safety in healthcare settings; it highlights the importance of product quality in protective equipment.

Source

Attributed to the FDA, recall number Z-1756-2026.

Original source: FDA Official Notice ↗

All FDA Recalls →

Nationwide notices with similar length or severity timing 8

Two Areazine-derived peer sets for this FDA recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.

Frequently Asked Questions

Common questions about this FDA recall.

What is this FDA recall about?
Burlington Medical, LLC is recalling 14,323 Frontal Aprons due to potential attenuation degradation that could shorten their lifespan, affecting devices distributed nationwide in the US and internationally.
Which agency issued this alert?
This alert was issued by FDA. The original notice is available at the source link at the bottom of this article.
How severe is this alert?
This alert is classified as "medium" severity. Stay informed and follow agency guidance.
What area is affected?
This alert affects United States. Check with FDA for the most current geographic scope.
Where can I find more FDA Recalls updates?
Browse the full FDA Recalls feed on Areazine at areazine.com/recalls/fda/ for the latest updates from FDA and other agencies.